Castle Biosciences, Inc. · NASDAQ:CSTL
Castle Biosciences — Fact Sheet (August 2025)
2 slides from Castle Biosciences's fact sheet, Aug 4, 2025
Slide 1: Q2 2025 Fact Sheet
Q2 2025 FACT SHEET Empowering people, informing care decisions 1,166 1. The Novitas local coverage determination, or LCD, that included non-coverage language for DecisionDx- SCC, went into effect on April 24, 2025; 2. Effective May 2025, the IDgenetix test was discontinued. 96,071 28,145 $137 Excite
Slide 2: Adjusted Revenues and Adjusted Gross Margin Reconciliation
The table below presents the reconciliation of Adjusted Revenues and Adjusted Gross Margin, which are non-GAAP financial measures. Adjusted Revenues Net revenues (GAAP) $86,188 Revenue associated with test reports delivered in prior periods (6) Adjusted revenues (Non-GAAP) $86,182 Adjusted Gross Mar
Castle Biosciences — Fact Sheet (August 2025) on 6ix